Current Evidence on Vasa Previa without Velamentous Cord Insertion or Placental Morphological Anomalies (Type III Vasa Previa): Systematic Review and Meta-Analysis
Abstract:Vasa previa carries a high risk of severe fetal morbidity and mortality due to fetal hemorrhage caused by damage to unprotected fetal cord vessels upon membrane rupture. Vasa previa is generally classified into types I and II. However, some cases are difficult to classify, and some studies have proposed a type III classification. This study aimed to review the current evidence on type III vasa previa. A systematic literature search was conducted, and 11 articles (2011–2022) were included. A systematic review s… Show more
“…Ultrasound Obstet Gynecol 2024; 63: [24][25][26][27][28][29][30][31][32][33] Published online in Wiley Online Library (wileyonlinelibrary.com). DOI: 10.1002/uog.26315.…”
Section: Diagn óStico Prenatal Y Resultado Posnatal De La Vasa Previa...mentioning
confidence: 99%
“…In addition to the two well-described categories of VP, a third phenotype was reported recently, characterized by aberrant vessels leaving the placental surface and subsequently returning to the placental mass with a 'boomerang orbit', in the absence of a velamentous cord insertion or a bilobed/succenturiate placenta (Figure 5) 9,10,29,30 . In view of our findings, we would like to challenge this definition of Type-III VP: the presence of a velamentous cord insertion or succenturiate lobes does not define per se VP Type I and Type II, respectively, since aberrant vessels of Type-III VP can coexist along with placental or cord abnormalities, as long as these structures are not adjacent to the internal os and the aberrant vessel represents the only vascular structure in the lower uterine segment 12,[24][25][26] .…”
ObjectiveVasa previa (VP) is a condition characterized by fetal blood vessels located on the amniotic membranes and outside the placenta, within 2 cm from internal os. The most common forms of VP are associated to velamentous cord insertion (type I) or to bilobed‐succenturiate placenta (type II), located across the cervix. A rare form of VP, not necessarily associated to other placental or vascular anomalies, involves aberrant vessels running from the placenta to the amniotic membranes, nearby the internal os, and then turning back to the placenta (type III). Although early diagnosis of type III VP is important, it often technically challenging and difficult. The objective of our study is to gather the current available evidence on type III VP related to prenatal diagnosis and perinatal outcome.MethodsA systematic review of the literature was carried out according to PRISMA guidelines from inception up to March 2023 using common internet‐based databases (PubMed, Scopus and EMBASE) looking for perinatal diagnosis of atypical type III vasa previa. Data extraction and tabulation was carried out by two different operators and double‐checked by a third senior author. Quality assessment of the included studies was realized using the National Institute of Health (NIH) tool for the quality assessment of Case Series Studies. Recent unpublished cases were searched in our local ultrasound database. Frequencies and proportions of prenatally vs. postnatally diagnosed type III VP were summarized, including clinical expression and perinatal outcomes.ResultsEighteen cases of type III VP were detected: 16 with prenatal diagnosis (14 from 10 publications and 2 unpublished from our center) and 2 with postnatal diagnosis from two publications. All cases with prenatal diagnosis were assessed by transvaginal ultrasound at a mean gestational age of 29 weeks (median 31 weeks; range 19‐38 weeks). Conception was achieved with IVF in 4/16 (25%), there were no prenatal symptoms in 15/18 cases (83.3%), in two cases (11.1 %) there was vaginal bleeding and in one (5.6%) preterm labour. Only 3/18 (16.6%) cases had no placental abnormality and 15/18 (83.3 %) showed at least one placental abnormality including: low‐lying insertion (9/17), succenturiate or accessory lobe (1/17), velamentous cord insertion (3/18), marginal insertion (9/18). All cases with prenatal diagnosis were liveborn with cesarean section before rupture of membranes at a mean gestational age of 35.4 weeks (range 32‐38) without neonatal complications. Emergent cesarean section was observed in 2/16 cases with prenatal diagnosis and 1/2 cases with postnatal diagnosis (rates: 12.5% vs 50%; p‐value: 0.179), Apgar score≤7 at 1 or 5 minutes in prenatally vs postnatally diagnosed cases was observed in 5/16 vs 1/2 cases (p=0.595) and 3/16 vs 1/2 cases (p=0.316), respectively.ConclusionsThe prenatal diagnosis of VP type III is challenging with few cases reported in the literature; however, it minimizes the risks of an adverse outcome with intact membranes early‐term elective cesarean delivery. Since clinical manifestations and risk factors are not specific, and type III VP cannot be excluded when there is a normal cord insertion or just one placental mass, a generalized screening by transvaginal ultrasound in the general population is recommended, particularly in presence of low‐lying or morphologically abnormal placentas and medically assisted reproduction.This article is protected by copyright. All rights reserved.
“…Ultrasound Obstet Gynecol 2024; 63: [24][25][26][27][28][29][30][31][32][33] Published online in Wiley Online Library (wileyonlinelibrary.com). DOI: 10.1002/uog.26315.…”
Section: Diagn óStico Prenatal Y Resultado Posnatal De La Vasa Previa...mentioning
confidence: 99%
“…In addition to the two well-described categories of VP, a third phenotype was reported recently, characterized by aberrant vessels leaving the placental surface and subsequently returning to the placental mass with a 'boomerang orbit', in the absence of a velamentous cord insertion or a bilobed/succenturiate placenta (Figure 5) 9,10,29,30 . In view of our findings, we would like to challenge this definition of Type-III VP: the presence of a velamentous cord insertion or succenturiate lobes does not define per se VP Type I and Type II, respectively, since aberrant vessels of Type-III VP can coexist along with placental or cord abnormalities, as long as these structures are not adjacent to the internal os and the aberrant vessel represents the only vascular structure in the lower uterine segment 12,[24][25][26] .…”
ObjectiveVasa previa (VP) is a condition characterized by fetal blood vessels located on the amniotic membranes and outside the placenta, within 2 cm from internal os. The most common forms of VP are associated to velamentous cord insertion (type I) or to bilobed‐succenturiate placenta (type II), located across the cervix. A rare form of VP, not necessarily associated to other placental or vascular anomalies, involves aberrant vessels running from the placenta to the amniotic membranes, nearby the internal os, and then turning back to the placenta (type III). Although early diagnosis of type III VP is important, it often technically challenging and difficult. The objective of our study is to gather the current available evidence on type III VP related to prenatal diagnosis and perinatal outcome.MethodsA systematic review of the literature was carried out according to PRISMA guidelines from inception up to March 2023 using common internet‐based databases (PubMed, Scopus and EMBASE) looking for perinatal diagnosis of atypical type III vasa previa. Data extraction and tabulation was carried out by two different operators and double‐checked by a third senior author. Quality assessment of the included studies was realized using the National Institute of Health (NIH) tool for the quality assessment of Case Series Studies. Recent unpublished cases were searched in our local ultrasound database. Frequencies and proportions of prenatally vs. postnatally diagnosed type III VP were summarized, including clinical expression and perinatal outcomes.ResultsEighteen cases of type III VP were detected: 16 with prenatal diagnosis (14 from 10 publications and 2 unpublished from our center) and 2 with postnatal diagnosis from two publications. All cases with prenatal diagnosis were assessed by transvaginal ultrasound at a mean gestational age of 29 weeks (median 31 weeks; range 19‐38 weeks). Conception was achieved with IVF in 4/16 (25%), there were no prenatal symptoms in 15/18 cases (83.3%), in two cases (11.1 %) there was vaginal bleeding and in one (5.6%) preterm labour. Only 3/18 (16.6%) cases had no placental abnormality and 15/18 (83.3 %) showed at least one placental abnormality including: low‐lying insertion (9/17), succenturiate or accessory lobe (1/17), velamentous cord insertion (3/18), marginal insertion (9/18). All cases with prenatal diagnosis were liveborn with cesarean section before rupture of membranes at a mean gestational age of 35.4 weeks (range 32‐38) without neonatal complications. Emergent cesarean section was observed in 2/16 cases with prenatal diagnosis and 1/2 cases with postnatal diagnosis (rates: 12.5% vs 50%; p‐value: 0.179), Apgar score≤7 at 1 or 5 minutes in prenatally vs postnatally diagnosed cases was observed in 5/16 vs 1/2 cases (p=0.595) and 3/16 vs 1/2 cases (p=0.316), respectively.ConclusionsThe prenatal diagnosis of VP type III is challenging with few cases reported in the literature; however, it minimizes the risks of an adverse outcome with intact membranes early‐term elective cesarean delivery. Since clinical manifestations and risk factors are not specific, and type III VP cannot be excluded when there is a normal cord insertion or just one placental mass, a generalized screening by transvaginal ultrasound in the general population is recommended, particularly in presence of low‐lying or morphologically abnormal placentas and medically assisted reproduction.This article is protected by copyright. All rights reserved.
“…The risk to the fetus can be significantly decreased by having a cesarean section performed before the membranes rupture. (2), (3) Here, we describe a vasa previa that was unintentionally discovered during a physical examination and ultrasound while the patient was 39 weeks pregnant and exhibiting labor symptoms.…”
Vasa previa refers to the state of fetal vasculature running within the membranes covering the cervix and under the presenting region of the fetus without being shielded by the placenta or umbilical cord. Due to its membranous vessels, the risk of compression or rupture could result in fetal demise, exsanguination, or even death. The cause is unknown, although risk factors include placenta previa, velamentous cord insertion, bilobed or succenturiate-lobed placentas, multiple pregnancies, and IVF-related pregnancies. In this article, we'll present a single instance of vasa previa discovered after an ultrasound and physical examination performed on a patient 39 weeks pregnant who came with complaints of bleeding from the birth canal-like signs of labor.
Keywords: Vasa Previa, Pregnancy, Velamentous Cord Insertion, Bleeding, Fetal Demise
“…A number of recent publications have described Type-3 vasa previa, a variant of vasa previa in which fetal vessels run unprotected over the cervix from one placental edge to another in a placenta that does not have a velamentous cord insertion or accessory lobes [1][2][3] . Because most cases of Type-3 vasa previa have a normal cord insertion, relying merely on the identification of a velamentous cord insertion or the presence of accessory lobes as risk factors for vasa previa will inevitably miss some cases, potentially leading to avoidable perinatal death.…”
mentioning
confidence: 99%
“…In 2004, we described a variant of vasa previa in which there was a normal cord insertion and a single placental lobe, Oyelese but fetal vessels ran from one edge of the placenta to another 10 . This was subsequently termed 'Type-3 vasa previa' [1][2][3] . We hypothesized that this variant arose from placenta previa in early pregnancy, followed by atrophy of the placental tissue overlying the cervix, leaving behind unprotected fetal vessels running over the cervix 10 .…”
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.